Camptothecin (CPT), a natural alkaloid isolated from Camptotheca acuminata, was first reported by Wall et al. to have a potent antitumor activity against a broad spectrum of tumors [1, 2] . As soon as the identification of the enzyme Topoisomerase I (TopoI) as the major cellular target of CPT was confirmed (with the discovery of overexpressed levels of TopoI in tumor cells relative to normal cells), the elucidation of the structure-activity relationship of the alkaloid and the molecular mechanism of inhibition were priority in many investigations in the area of medicinal chemistry [3] .
It is well established that successful inhibition of TopoI requires an unmodified lactone E ring moiety in the structure, however, the pHdependent reversible equilibrium of the α-hydroxy-δ-lactone ring is shifted toward the carboxilate open-ring form at physiological pH or above [4] .
CPTs are S-phase-specific drugs and the stabilization of the covalent TopoI-DNA complex by CPT is a required step in its antitumor activity.
Because of that, prolonged or repetitive exposure of this kind of drugs is necessary to increase cell killing, since the S phase is a short phase of the cell cycle [5] .
Several CPT derivatives have been developed to improve the lactone stability and to limit the uncontrolled toxic effects. Among them, Topotecan (Hycamtin®) [6] and Irinotecan (Camptosar®) [7] are the only two analogs approved for clinical practice. While Irinotecan is used exclusively by i.v. infusion, Topotecan is also administered by oral route for the treatment of relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response who are ≥45 days from the end of first-line chemotherapy Further studies focused on the nature of the CPT derivatives, argue that highly lipophilic analogues provide several pharmaceutical advantages relative to water-soluble such as lactone stability, lack of metabolic conversion, broad antitumor activity, oral bioavailability and optimized therapeutic efficiency [9, 10] .
According to previous modifications of CPT, additional ring combination in positions 10-11, 7-9 and 9-10 showed potent antitumor activity, probably due to the extended planarity exerted by an additional hexacyclic-fussed ring [11] . Oxazines, amidines, furan and dihydrofuran rings fussed on CPT structure have been extensively studied with exceptional in vitro results [12, 13, 14] . 9,10-[1,3]-Dioxocamptothecin (CDiox), which can be regarded as a close structural variant of 9,10-(ethylendioxy) CPT, has not been considered for any prior study in spite of being as active as CPT in enhancing topo I-mediated cleavage of the DNA duplex [15, 16] . In addition, no violations of Lipinski rules, adequate polar surface area and a lipophilic cLogP value, complete a favorable theoretical calculation behavior for developing a more consistent study for this hexacyclic derivative [17] .
On the basis of the lipophilic behavior of CDiox and the promising results published for other water-insoluble CPT derivatives [18] , a preliminary study to establish the oral availability of this analogue is presented in this work. To elucidate permeability and transport mechanism, experiments were carried out using Caco-2 cells and in situ perfusion studies in rats.
Results and Discussion

Chemistry
CDiox was prepared by straightforward condensation of 10-hydroxycamptothecin with an excess of formaldehyde in neat triflic acid.
Although the reaction is effective in solvents such as nitromethane, acetic acid and acetonitrile with catalytic amounts sulfuric acid or triflic acid at 50ºC, optimal conditions were obtained by performing the synthesis in neat triflic acid from 0ºC to room temperature overnight. The derivative was characterized by means of 1 H-NMR, 13 C-NMR, elemental analysis and exact mass. In the best of our knowledge no synthesis has been previously reported for this drug 2.2 Biological studies.
Cytotoxicity
The in vitro antitumor activity of CDiox was assayed by MTT method against five human cancer cell lines, including cervical cancer (HeLa), colon adenocarcinoma (Caco-2), malignant melanoma (A375), T cell lymphoblast (Jurkat), and breast cancer hormone sensitive cell line (MDA-MB-231). CPT as parent compound and Rubitecan and Topotecan as well known effective oral CPT derivatives were used as reference drugs. IC50
(µM) values are expressed in Table 1 . In vitro antitumor activity of CDiox analog and reference compounds against five human tumor cell lines, were measured by the MTT assay after 24h of incubation and expressed as IC50 (µM)
Flow cytometry assay. Apoptosis induction
Cell death mechanism was investigated using Annexin V-FITC/PI flow cytometry assay. Experiments allow analyzing whether CDiox, CPT, Rubitecan and Topotecan were able to induce apoptosis in Caco-2 cells at concentrations of 0.05µM and 0.5 µM after 24h of incubation. In order to determine if the apoptosis induced by the compounds is time dependent, assays were also carried out after 48 h of incubation.
As shown in Table 2 
Q1 quadrant (necrotic cells). Q2 quadrant (late apoptotic cells). Q3 quadrant (normal cells). Q4 quadrant (early apoptotic cells).
Measurement of DNA synthesis
Since TopoI inhibition has been shown to be a feasible strategy to block cancer cell proliferation, the effect of the compounds on 
Apoptosis pathway: evaluation of the role of p53 Pho-p53
In order to obtain more insights about the apoptosis pathway, the expression of the pro-apoptotic p53 and its activated form pho-p53 (Ser15) This is an interesting finding that suggests two different apoptotic-induced mechanisms by these compounds depending on the cell type studied.
In vitro permeability
CPT, as parent compound, and Topotecan, as the only camptothecin derivative approved for oral administration, were selected to be compared with CDiox to measure in vitro permeability values using Caco-2 monolayer in both apical to basal (Pab) and in basal to apical (Pba) directions at different concentrations.
Results are presented in Figure 5 . It is well-known that the main limitation of Topotecan is that it is substrate of efflux transporters such as Pgp and BCRP [23, 24] . As consequence, the oral fraction absorbed of orally administered Topotecan is less than 45%
and it has been observed high interindividual variability in plasma levels after oral administration.
In order to evaluate if CDiox is substrate of energy dependent transporter permeability, assays were carried out in presence of Sodium azide (SAz) as metabolic inhibitor [25] . The presence of SAz leads to inhibition of the active carrier mediated processes by depletion of ATP resources in the cells.
Results in presence of the metabolic inhibitor show that permeability values of CDiox ( Table 3 : Permeability values of CDiox at 50µM in presence and in absence of Sodium Azide (SAz)
The determination of permeability parameter (Peff) in preclinical studies is a crucial step to determine the suitability of the candidates for oral administration in early stages. Table 4 . Predicted values of oral fraction absorbed (conc. 50µM) A high oral fraction absorbed (higher than 50%) is necessary to be a potential oral drug candidate. Lower values would difficult the development of an oral product and lead to the selection of other extravasal (intramuscular) or intravenous route. Preliminary results indicate that CDiox is a good candidate for oral administration. Its permeability value at 50 µM is 5-fold higher than Topotecan and slightly higher than CPT, showing no (or minimum) affinity for Pgp, which could be a favorable behavior due to this transporter is a common resistance mechanism in tumor tissues. 
In situ permeability. Rat perfusion assay
In situ outcomes, carried out using perfusion rat model, are in accordance with obtained from cell culture assays.
Absorption rate constants, Ka, and Peff values, are higher for hexacyclic derivative than for CPT and Topotecan. In addition, CDiox displays much better absorption profile than a well known high oral permeability standard
Metropolol. (Table 5 and Figure 7 ). Transport studies, carried out using Caco-2 cell monolayers and in situ perfusion in rat, indicated that the permeability is clearly better than for Topotecan, thus ensuring a higher oral fraction absorbed. Moreover, mechanistic studies showed that CDiox is not a Pgp substrate, which is an important goal for an anticancer drug as it ensures less variable drug absorption and broad tissue distribution as well as much better penetration to cancer cells. CDiox showed a promising antitumor profile and improvement as an effective drug for oral administration
Experimental protocols
Chemistry
Materials and instruments
All reagents and solvents were reagent grade. 10-Hydroxycamptothecin was purchase by AKScientific. Formaline, triflic acid, H 2 SO 4, and standard solvents were purchase from Sigma Aldrich. Column chromatography was carried out on silica gel (Merck 200-300 mesh). TLC analysis was elaborated on silica gel plates (Merck 60F 254 ). 1 H NMR and 13 C NMR spectra were recorded in DMSO-d 6 at 300MHz with a Bruker instrument.
Mass spectra were recorded using an Acquity UPLC system (Waters Corp.)
The separation was carried out on a C18 column (50 mm × 2.1 mm i.d.,
1.7μm). The analysis was achieved with gradient elution using methanol and water (containing 0.01% formic acid) as the mobile phase. The injection volume was 2μL. The spectrometer was connected to the UPLC system via electrospray ionization (ESI) interface. The ESI source was operated in positive ionization mode with the capillary voltage at 3.0 kV
Chemical synthesis
To a neat mixture of solid 10-hydroxycamptothecin and formaldehyde solution (36%) was added drop wise triflic acid at 0ºC. After being stirred for 12h at room temperature, ice water was added and the precipitated was purified by column chromatography to give CDiox 
Biological assays
Cell culture conditions attached to Supp. Inf.
Cytotoxic studies
The in vitro antiproliferative activity was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [26] .
Cells were seeded in a total volume of 200 µL of culture medium in 96-well microtiter plates with flat-bottomed wells at a density of 25000 cells per well. Cultures were incubated at 37 ºC in a 5% carbon dioxide atmosphere. 24 h later, the medium was replaced with a fresh medium and compounds at increasing concentrations were added. Samples solutions were prepared in DMSO 0.1% or miliQ water in the case of Topotecan.
Plates were incubated for 24, 48, or 72 h and then, 20 µL of MTT solution (5 mg/mL) were added to each well. The samples were incubated at 37ºC
for 3 h to allow reaction for the formazan formation. Absorbance was measured at 570 nm with a Labsystems Multiskan EX plate reader and the values were corrected with reference to the measurement at 630 nm.
Flow cytometry assay
The nature of compounds effects on the cells was determined with the aid of flow cytometry, after the double staining with propidium iodide (PI) and annexin V-fluorescein isothiocyanate (annexinV) [27] . The flow cytometry analyses were carried out by using a Beckman Coulter EPICS XL-MCL cytometer. Cells were stained using the annexin V-fluoresceinisothiocyanate apoptosis detection kit (Roche) that provides a double staining with PI and annexinV [27] .
Measurement DNA synthesis
Proliferation 
Total protein extraction
Total protein extracts were extracted from approximately 10 6 cells lysed in ice for 15 min using 100 µL of lysis buffer (20 mM Hepes, pH 7.4, 1% Triton X-100, 100 mM NaCl, 50 mM, NaF, 10 mM, β-glycerophosphate, 1 mM activated sodium orthovanadate, 1 mM PMSF and 2 µL/mL protein proteases inhibitor cocktail). Then, the suspension was spun-down at 13,000 xg for 10 min at 4 ºC, and supernatants were collected and stored at -80 ºC until their use. Protein content was determined by a modified Lowry method [28] .
Western blot analysis
Western blotting is an important technique used for identifying specific proteins from a complex mixture of proteins obtained from cells. Aliquots of cell lysates (30 μg protein) were added to sample buffer containing 10% β-mercaptoethanol and the mixture was immediately boiled during 5 min.
Proteins were separated by electrophoresis in sodium dodecyl sulfatepolyacrylamide (12%) gels (SDS-PAGE), at 100 V during 2 h. After that, the proteins were electroblotted (Bio-Rad) onto nitrocellulose membranes.
Membranes were blocked with 0.05 g/ml non-fat milk or with 0.05 g/ml BSA in TBS containing 0.2% Tween 20 (TBST), depending on the antibody, washed three times at room temperature, and incubated for 2 h at room temperature with primary antibodies diluted in TBST with 0.01 g/ml non-fat milk as follows, hsp70 ( 
Transport studies
Cell monolayer cultures
Cell monolayers were prepared by seeding 400,000 cells on each polycarbonate membrane placed in the base of transwell inserts (MILLICEL  -PCF, surface area 4.2 cm 2 , 0,4 µm pore size) [29, 30] .
Cultures were grown in Dulbecco's modified Eagle's media, as described previously until confluence during 19-22 days maintaining the cultures at standard conditions of 37C under 90% humidity and 5% CO 2 [31] . The integrity of each cell monolayer was tested by measuring its transepithelial electrical resistance (TEER) value before and after each transport assay.
Normal TEER values for Caco-2 monolayers were ranging 500-750 cm 2 [32] . Cell monolayers with TEER values less than 420 cm 2 were discarded. Hank's balanced salt solution (HBSS) (9.8 g/L) supplemented HEPES (5.96 g/L) was used for all the experiments after adjusting pH to the desired value.
In vitro permeability determination
The in vitro transport study was developed using the Caco-2 cell monolayers (ATCC) with an appropriate trans-epithelial electrical resistance (TEER) value.
Tested compound solutions were loaded into the donor side and buffer was added to the receiver chamber of each well. The six-well plate containing the inserts with the cell monolayers was put into an orbital environmental shaker maintained at a constant temperature (37 C) and agitation rate (50 rpm) during all the experiments. To carry out transport assays in presence of SAz, it was always placed on both sides of the cell monolayer. Four samples of 200 µL each were collected at 15, 30, 60 and 90 minutes in the receiver chamber and the volume was replaced each time with fresh buffer.
Moreover, two samples of 200 µL each were taken at the start and the end of the assay from the donor chamber.
HPLC analysis and pharmacokinetics parameters are described in Supp.
Inf.
In situ assays: rat perfusion studies
Male Wistar rats were weighted after two hours fast with access to water.
Rats were anesthetized using a mixture of diazepam (Valium, Roche) (1.67 mg/kg), ketamine (Ketolar; Parke-Davis) (50 mg/kg) and atropine (atropine Water reabsorption studies and permeability values are described in Supp.
